---
title: "\"First H then A\" second deal of the year: After raising nearly 1.8 billion in Hong Kong stocks, DUALITYBIO is preparing for the Sci-Tech Innovation Board"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/261855797.md"
description: "As A-share companies rush to the Hong Kong Stock Exchange, reverse operations are quietly rising. Recently, DUALITYBIO announced plans to go public on the Sci-Tech Innovation Board"
datetime: "2025-10-20T09:37:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/261855797.md)
  - [en](https://longbridge.com/en/news/261855797.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/261855797.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/261855797.md) | [English](https://longbridge.com/en/news/261855797.md)


# "First H then A" second deal of the year: After raising nearly 1.8 billion in Hong Kong stocks, DUALITYBIO is preparing for the Sci-Tech Innovation Board

As A-share companies rush to the Hong Kong Stock Exchange, reverse operations are quietly rising.

Recently, DUALITYBIO-B (9606.HK) announced plans to list on the Sci-Tech Innovation Board.

**This is another project of a Hong Kong-listed company planning to return to A-shares, following the successful registration with the Securities Regulatory Commission of the first "H first, then A" deal this year, BaiAoSaiTu (2315.HK).**

With the warming of the A-share IPO market, there is anticipation of more Hong Kong companies starting their journey back to A-shares.

However, DUALITYBIO-B's path to an IPO on the Sci-Tech Innovation Board may face certain controversies.

On one hand, as a biopharmaceutical company, DUALITYBIO-B currently has no approved drugs on the market and primarily generates revenue through a "License-out" model, which involves obtaining upfront payments, milestone payments, and sales shares by licensing self-developed candidate drugs. This leads to instability in its revenue.

Although DUALITYBIO-B achieved revenue of 1.227 billion yuan through licensing deals with pharmaceutical companies like GSK in the first half of 2025, it remains in a loss-making situation, with a net loss of 292 million yuan during the same period, expanding more than six times year-on-year.

Looking at several biopharmaceutical companies that are about to land on the Sci-Tech Innovation Board this year, basic profitability is in sight.

BaiAoSaiTu, which focuses on animal models, achieved a net profit of 48 million yuan in the first half of 2025; while Wuhan Heyuan Biotechnology Co., Ltd., which is about to issue its IPO, has not yet turned a profit, its core product, plant-derived recombinant human serum albumin injection, has been approved for market, with profitability imminent.

On the other hand, the necessity for DUALITYBIO-B's financing faces challenges.

In April of this year, DUALITYBIO-B listed on the Hong Kong Stock Exchange, raising nearly 1.8 billion yuan, which has supplemented its R&D funding.

As of the end of June 2025, DUALITYBIO-B's cash and cash equivalents amount to nearly 3 billion yuan.

In this context, whether DUALITYBIO-B can gain market recognition for its financing plan on the Sci-Tech Innovation Board remains to be further observed

### 相關股票

- [DUALITYBIO-B (09606.HK)](https://longbridge.com/zh-HK/quote/09606.HK.md)

## 相關資訊與研究

- [BREAKINGVIEWS-Apollo reaps rich rent on its Intel lifeline](https://longbridge.com/zh-HK/news/281406220.md)
- [Nvidia Stock (NVDA) Braces for a Quick Snapback after a Rare Two-Quarter Losing Streak](https://longbridge.com/zh-HK/news/281360100.md)
- [Nvidia Makes Equity Investment In Marvell Technology, Deepens NVLink Fusion Partnership](https://longbridge.com/zh-HK/news/281388869.md)
- [Xpeng Mar deliveries rebound sequentially despite year-on-year decline](https://longbridge.com/zh-HK/news/281331957.md)
- [Several Baidu Apollo Go Robotaxis Freeze In China, Raising Concerns About AV Safety: Report](https://longbridge.com/zh-HK/news/281345987.md)